Whole-body CD8⁺ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.

ABSTRACT: Chimeric antigen receptor T-cell therapy (CART) has revolutionized the treatment of patients with refractory/relapsed large B-cell lymphoma (R/R LBCL). Limited biopsy data indicate that a higher activated CD8⁺ T-cell density is associated with tumor response. However, tumor biopsies fail to capture the systemic kinetics of CD8⁺ T-cells. Therefore, we conducted an exploratory phase 2 single-arm trial utilizing a zirconium-89-labeled one-armed anti-CD8α antibody (⁸⁹ZED88082A) to enable whole-body imaging of CD8⁺ T-cells through positron emission tomography (PET) (NL9034; EUCTR2020-004749-35-NL). Imaging analysis was performed in 23 patients with R/R LBCL, encompassing 251 lesions before (pre-CART) and after infusion (post-CART). Primary endpoint wa

SUBMITTER: de Boer JW 

PROVIDER: S-EPMC12749833 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature